SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, ...

SOUTH SAN FRANCISCO, Calif., April 23, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Unity Biotechnology (UBX – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $2.19.

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ...

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment ...

Unity Biotech (NASDAQ: UBX) is developing drug candidates to extend the number of years humans can live unburdened by disease, but investors might appreciate it if the small-cap pharma focused just a ...